2017
Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival
Yang JC, Risch E, Zhang M, Huang C, Huang H, Lu L. Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival. Future Oncology 2017, 13: 1981-1990. PMID: 28829218, DOI: 10.2217/fon-2017-0084.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAgedAged, 80 and overBiomarkers, TumorCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansInsulin-Like Growth Factor IIMethyltransferasesMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPrognosisSurvival RateConceptsOvarian cancer survivalIGF-IICancer survivalOvarian cancerDisease progression-free survivalMultivariate Cox regression modelProgression-free survivalRisk of deathCox regression modelIGF-II expressionClinical followSurvival analysisClinical implicationsIGFNormal tissuesHeterogeneous outcomesSurvivalCancerMolecular signaturesAssociationRegression modelsRNA sequencingSupNSUN2Relapse
2016
LIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis
Lu L, Katsaros D, Canuto EM, Biglia N, Risch HA, Yu H. LIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis. Gynecologic Oncology 2016, 141: 121-127. PMID: 26751131, DOI: 10.1016/j.ygyno.2015.12.035.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancer prognosisOvarian cancer prognosisMolecular subtypesCancer prognosisSurvival analysisMultivariate Cox regression modelKaplan-Meier survival curvesEpithelial ovarian cancer tissuesCox regression modelEpithelial ovarian cancerReduced relapse riskOvarian cancer tissuesIGF-II mRNAQuantitative reverse transcription PCRRelapse riskReverse transcription-PCROvarian cancerBetter survivalCancer tissuesLin-28BSurvival curvesClinical implicationsIGFPrognosisSubtypes
2015
H19 lncRNA alters DNA methylation genome wide by regulating S-adenosylhomocysteine hydrolase
Zhou J, Yang L, Zhong T, Mueller M, Men Y, Zhang N, Xie J, Giang K, Chung H, Sun X, Lu L, Carmichael GG, Taylor HS, Huang Y. H19 lncRNA alters DNA methylation genome wide by regulating S-adenosylhomocysteine hydrolase. Nature Communications 2015, 6: 10221. PMID: 26687445, PMCID: PMC4703905, DOI: 10.1038/ncomms10221.Peer-Reviewed Original ResearchMeSH KeywordsAdenosylhomocysteinaseAnimalsDNA (Cytosine-5-)-MethyltransferasesDNA MethylationGenomeHumansInsulin-Like Growth Factor IIMiceProtein BindingRNA, Long NoncodingS-AdenosylhomocysteineConceptsS-adenosylhomocysteine hydrolaseCellular componentsDNA methylation genomeGenome-wide methylation profilingOnly mammalian enzymeNumerous gene lociS-adenosylhomocysteineMode of regulationDiverse cellular componentsMethylation genomeMammalian developmentMethylation dynamicsIgf2-H19Mammalian enzymeRegulatory circuitsDNA methylationDependent methyltransferasesMethylation changesMethylation profilingPotent feedback inhibitorEpigenetic alterationsGene locusH19 lncRNAFeedback inhibitorS-adenosylmethionine
2013
An insulin-like growth factor-II intronic variant affects local DNA conformation and ovarian cancer survival
Lu L, Risch E, Deng Q, Biglia N, Picardo E, Katsaros D, Yu H. An insulin-like growth factor-II intronic variant affects local DNA conformation and ovarian cancer survival. Carcinogenesis 2013, 34: 2024-2030. PMID: 23677070, DOI: 10.1093/carcin/bgt168.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor IIIGF-II expressionPatient survivalGrowth factor IIPresence of carboplatinChemotherapy responseOvarian cancerCox proportional hazards regression modelKaplan-Meier survival curvesProportional hazards regression modelsFactor IIOvarian cancer tissue samplesIGF-II genotypeAdjusted hazard ratioOvarian cancer survivalHazards regression modelsCommercial enzyme-linked immunosorbentQuantitative reverse transcription polymerase chain reactionReverse transcription-polymerase chain reactionOvarian cancer developmentTranscription-polymerase chain reactionCancer tissue samplesEnzyme-linked immunosorbentHazard ratioSNP genotyping assays
2010
IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics.
Qian B, Katsaros D, Lu L, Canuto EM, Benedetto C, Beeghly-Fadiel A, Yu H. IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics. Oncology Reports 2010, 25: 203-13. PMID: 21109978, PMCID: PMC3075064, DOI: 10.3892/or_00001062.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDisease-Free SurvivalDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor IIMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPromoter Regions, GeneticReverse Transcriptase Polymerase Chain ReactionConceptsInsulin-like growth factor IIEpithelial ovarian cancerOvarian cancerDisease progressionResidual tumor sizeIGF-II peptideFresh tumor samplesIGF-II expressionPromoter-specific expressionIGF-II mRNAGrowth factor IIIGF-II promotersLower mRNA expressionOverall survivalAggressive diseasePoor prognosisTumor sizeDisease characteristicsMethylation-specific PCRTumor gradeTreatment responseIGF-II transcriptionPromoter-specific methylationClinical implicationsCancer
2009
Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II
Lu L, Katsaros D, Shaverdashvili K, Qian B, Wu Y, de la Longrais IA, Preti M, Menato G, Yu H. Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II. European Journal Of Cancer 2009, 45: 2212-2218. PMID: 19477633, DOI: 10.1016/j.ejca.2009.05.003.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overDNA-Binding ProteinsFemaleHumansInsulin-Like Growth Factor IIMicroRNAsOvarian NeoplasmsPluripotent Stem CellsRNA-Binding ProteinsSurvival AnalysisConceptsEpithelial ovarian cancerIGF-II expressionIGF-IIOvarian cancerPrimary epithelial ovarian cancerInsulin-like growth factor IIUnfavourable prognostic markerOvarian cancer progressionPotential therapeutic targetLin-28BGrowth factor IIStem cellsIGFBP-3Overall survivalDisease progressionPrognostic markerDisease outcomeDisease featuresTherapeutic targetTumor growthTumor samplesFactor IICancer treatmentCancer progressionGrowth factor
2008
Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics
Mu L, Katsaros D, Wiley A, Lu L, de la Longrais IA, Smith S, Khubchandani S, Sochirca O, Arisio R, Yu H. Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics. Breast Cancer Research And Treatment 2008, 115: 151. PMID: 18481170, DOI: 10.1007/s10549-008-0046-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsFemaleGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like Growth Factor IIMiddle AgedPeptidesPrognosisProportional Hazards ModelsRecurrenceRNA, MessengerConceptsIGFBP-3IGFBP-3 proteinIGF-IIBreast cancerMRNA expressionTissue levelsHigher mRNA expressionHigh IGFBP-3 expressionProportional hazards regression modelsEarly TNM stageIGFBP-3 expressionHazards regression modelsRisk of relapseIGF-II peptideFresh tumor samplesIGF mRNA expressionIGF-II expressionIGF-I transcriptsReal-time RT-PCRDisease recurrenceFavorable prognosisPeptide concentrationPatient survivalDisease characteristicsTNM stageKlotho Expression in Epithelial Ovarian Cancer and its Association with Insulin-Like Growth Factors and Disease Progression
Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H. Klotho Expression in Epithelial Ovarian Cancer and its Association with Insulin-Like Growth Factors and Disease Progression. Cancer Investigation 2008, 26: 185-192. PMID: 18259951, DOI: 10.1080/07357900701638343.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCystadenocarcinoma, SerousDisease ProgressionEpithelial CellsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGlucuronidaseHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like Growth Factor IIKlotho ProteinsMiddle AgedNeoplasm StagingOvarian NeoplasmsPrognosisReverse Transcriptase Polymerase Chain ReactionRNA, NeoplasmSurvival RateConceptsEpithelial ovarian cancerKlotho expressionOvarian cancer progressionDisease progressionOvarian cancerCox proportional hazards regression modelTumor tissueProportional hazards regression modelsCancer progressionInsulin-like growth factorResidual tumor sizeAction of IGFOvarian cancer patientsExpression of IGFHazards regression modelsOvarian cancer prognosisEpithelial ovarian cancer progressionExpression of totalFresh tumor tissueWarrants further elucidationUnderwent surgeryIGFBP-3Patient ageClinical followTumor histology
2007
Hypermethylation of let-7a-3 in Epithelial Ovarian Cancer Is Associated with Low Insulin-like Growth Factor-II Expression and Favorable Prognosis
Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in Epithelial Ovarian Cancer Is Associated with Low Insulin-like Growth Factor-II Expression and Favorable Prognosis. Cancer Research 2007, 67: 10117-10122. PMID: 17974952, DOI: 10.1158/0008-5472.can-07-2544.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor IIPossible epigenetic regulationLet-7 regulationEpithelial ovarian cancerLet-7aRole of miRNAsActivity of mRNAPromoter CpG island methylationCpG island methylationTumor suppressor geneIGF-II expressionMiRNA genesSmall RNAsEpigenetic regulationOvarian cancerDNA methylationCpG islandsMethylation-specific PCRReal-time reverse transcription PCRReverse transcription-PCRReal-time methylation-specific PCRSuppressor geneIsland methylationMethylationMiRNA expressionExpression of MDR1 in epithelial ovarian cancer and its association with disease progression.
Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Yu H. Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 2007, 16: 395-403. PMID: 17913048, DOI: 10.3727/000000006783980892.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsATP Binding Cassette Transporter, Subfamily B, Member 1Biomarkers, TumorBRCA1 ProteinCyclin-Dependent Kinase Inhibitor p16Disease ProgressionDrug Resistance, MultipleEstrogen Receptor alphaFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IIMiddle AgedNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousOvarian NeoplasmsPrognosisRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerRNA, NeoplasmSurvival AnalysisTreatment OutcomeConceptsMDR1 expressionClinicopathological parametersDisease progressionOvarian cancer cohortEpithelial ovarian cancerOvarian cancer prognosisOvarian cancer treatmentOvarian cancer progressionExpression of MDR1Ovarian tumor samplesOverall survivalPatient ageOvarian tumorsIGF-IIQuantitative real-time PCROvarian cancerCancer cohortReal-time PCRIndependent markerCancer prognosisDrug resistanceTumor samplesCancer treatmentCancer progressionERalpha
2006
Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer
Lu L, Katsaros D, Wiley A, de la Longrais I, Puopolo M, Schwartz P, Yu H. Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Gynecologic Oncology 2006, 103: 990-995. PMID: 16859738, DOI: 10.1016/j.ygyno.2006.06.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDisease ProgressionDNA PrimersFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor IIMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPromoter Regions, GeneticReverse Transcriptase Polymerase Chain ReactionRNA, MessengerConceptsIGF-II promotersResidual tumorOvarian cancerIGF-II transcriptionNon-serous histologyInsulin-like growth factor IISmall residual tumorLarge residual tumorLate-stage diseaseEpithelial ovarian cancerOvarian cancer prognosisOvarian cancer progressionOvarian tumor samplesGrowth factor IIIGF-II geneOptimal debulkingQuantitative RT-PCRSerous histologyStage diseasePatient agePatient survivalDisease characteristicsDisease stageFetal growthIGF-IIThe relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer.
Lu L, Katsaros D, Wiley A, de la Longrais I, Risch HA, Puopolo M, Yu H. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clinical Cancer Research 2006, 12: 1208-1214. PMID: 16489075, DOI: 10.1158/1078-0432.ccr-05-1801.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorDisease ProgressionEpithelial CellsEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IIMiddle AgedNeoplasm StagingOvarian NeoplasmsReverse Transcriptase Polymerase Chain ReactionRNA, NeoplasmSurvival AnalysisConceptsIGF-II expressionEstrogen receptor alpha expressionReceptor alpha expressionEpithelial ovarian cancerIGF-IIDisease progressionOvarian cancerInsulin-like growth factor (IGF) systemPrimary epithelial ovarian cancerProtein 3Insulin-like growth factorIGF signalingHigh IGF-IILarge residual lesionExpression of estrogenInsulin-like growth factor IIIGFBP-3 expressionEffects of IGFOvarian cancer treatmentGrowth factor systemFresh tumor specimensGrowth factor IIQuantitative reverse transcription PCRIGFBP-3Serous histology